BioCentury
ARTICLE | Clinical News

iCo-007: Phase I start

January 29, 2007 8:00 AM UTC

This half, iCo will begin a dose-escalation Phase I trial. In 2005, ISIS granted iCo exclusive rights to the compound to treat eye diseases caused by choroidal neovascularization (see BioCentury, Aug....